$7.62
6.28% yesterday
Nasdaq, Feb 04, 10:00 pm CET
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

EyePoint Pharmaceuticals, Inc. Stock price

$7.62
-1.06 12.21% 1M
-0.98 11.40% 6M
+0.17 2.28% YTD
-20.17 72.58% 1Y
-1.72 18.42% 3Y
-11.78 60.72% 5Y
-31.68 80.61% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.45 6.28%
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

Key metrics

Market capitalization $520.07m
Enterprise Value $289.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.33
P/S ratio (TTM) P/S ratio 11.38
P/B ratio (TTM) P/B ratio 1.86
Revenue growth (TTM) Revenue growth 7.50%
Revenue (TTM) Revenue $45.71m
EBIT (operating result TTM) EBIT $-116.97m
Free Cash Flow (TTM) Free Cash Flow $-118.04m
Cash position $253.79m
EPS (TTM) EPS $-2.01
P/E forward negative
P/S forward 12.22
EV/Sales forward 6.80
Short interest 17.52%
Show more

Is EyePoint Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

EyePoint Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from EyePoint Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
46 46
8% 8%
100%
- Direct Costs 3.89 3.89
46% 46%
9%
42 42
19% 19%
91%
- Selling and Administrative Expenses 50 50
7% 7%
110%
- Research and Development Expense 107 107
73% 73%
235%
-116 -116
43% 43%
-253%
- Depreciation and Amortization 1.19 1.19
72% 72%
3%
EBIT (Operating Income) EBIT -117 -117
43% 43%
-256%
Net Profit -104 -104
3% 3%
-227%

In millions USD.

Don't miss a Thing! We will send you all news about EyePoint Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
6 days ago
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoing Phase 3 studies suggest significant upside potential, though past mixed results and heavy competition raise risks. Recent fundraising and a new manufacturing facility indicate strong commitment, ...
Neutral
GlobeNewsWire
6 days ago
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Bi...
Neutral
GlobeNewsWire
20 days ago
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in ...
More EyePoint Pharmaceuticals, Inc. News

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Duker
Employees 121
Founded 1987
Website www.eyepointpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today